New hope for aggressive breast cancer: experimental drug ESG401 enters final testing phase

NCT ID NCT06732323

Recruiting now Disease control Sponsor: Qilu Pharmaceutical Co., Ltd. Source: ClinicalTrials.gov ↗

First seen Jun 26, 2026 · Last updated Jun 26, 2026

Summary

This Phase 3 trial is testing a new drug called ESG401 against standard chemotherapy for people with advanced triple-negative breast cancer that has spread or come back. The study will enroll about 504 participants to see if ESG401 can delay cancer growth and improve survival. It's an open-label study, meaning everyone knows which treatment they are getting.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: ESG401 (a drug given by IV infusion)
What this could lead to: If successful, ESG401 could offer a new first-line treatment option for people with metastatic triple-negative breast cancer, potentially improving how long they live without their cancer getting worse.
What could go wrong: This is a Phase 3 trial, but it's still experimental. ESG401 may not prove better than existing chemotherapies, and it could have side effects. Results are not guaranteed.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for TRIPLE-NEGATIVE BREAST CANCER (TNBC) are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

triple-negative breast carcinoma

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

TRIPLE-NEGATIVE BREAST CANCER (TNBC)

Contacts and locations

Locations

Cancer Institute and Hospital, Chinese Academy of Medical Sciences
RECRUITING

Beijing, China

More trials for these conditions

Other studies related to the condition(s) this trial covers.